Molecular mechanisms of hookworm disease: Stealth, virulence, and vaccines - 27/06/12
, Leon Tribolet, BSc a, Cinzia Cantacessi, PhD a, Maria Victoria Periago, PhD b, Maria Adela Valerio, PhD c, Amar R. Jariwala, MD d, Peter Hotez, MD, PhD e, f, David Diemert, MD d, Alex Loukas, PhD a, Jeffrey Bethony, PhD d, ⁎ 
Abstract |
Hookworms produce a vast repertoire of structurally and functionally diverse molecules that mediate their long-term survival and pathogenesis within a human host. Many of these molecules are secreted by the parasite, after which they interact with critical components of host biology, including processes that are key to host survival. The most important of these interactions is the hookworm’s interruption of nutrient acquisition by the host through its ingestion and digestion of host blood. This results in iron deficiency and eventually the microcytic hypochromic anemia or iron deficiency anemia that is the clinical hallmark of hookworm infection. Other molecular mechanisms of hookworm infection cause a systematic suppression of the host immune response to both the parasite and to bystander antigens (eg, vaccines or allergens). This is achieved by a series of molecules that assist the parasite in the stealthy evasion of the host immune response. This review will summarize the current knowledge of the molecular mechanisms used by hookworms to survive for extended periods in the human host (up to 7 years or longer) and examine the pivotal contributions of these molecular mechanisms to chronic hookworm parasitism and host clinical outcomes.
Le texte complet de cet article est disponible en PDF.Key words : Hookworms, virulence factors, immune modulation, vaccines, proteases, Ancylostoma secreted proteins
Abbreviations used : APR, ASP, ES, GST, IDA, KI, L3, MIF, MMP, NAP, NIF, TIMP
Plan
| Series editors: Joshua A. Boyce, MD, Fred Finkleman, MD, William T. Shearer, MD, PhD, and Donata Vercelli, MD |
|
| Disclosure of potential conflict of interest: M. S. Pearson, A. Loukas, and J. Bethony have received research support from the Sabin Vaccine Institute. L. Tribolet has received research support from the Sabin Vaccine Institute and the National Health and Medical Research Council. P. Hotez is president of the Sabin Vaccine Institute. D. Diemert has received research support from the Sabin Vaccine Institute and the Government of The Netherlands. The rest of the authors declare that they have no relevant conflicts of interest. |
|
| Terms in boldface and italics are defined in the glossary on page 14. |
Vol 130 - N° 1
P. 13-21 - juillet 2012 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
